Patients
RA, autoimmune disease, Sjogren’s syndrome
SECONDARY, INFLAMMATORY DISEASE, AUTOIMMUNE DISEASE
Adult patients (≥ 18 years of age) with moderate-to-severe RA, defined as CDAI > 10, who were to initiate treatment with SC abatacept obtained via usual care as per judgement of the treating physician, prior to and independently of consideration for study enrolment, were eligible for enrollment. Additional inclusion criteria were: ≥ 18 years of age; moderate to severely active RA, defined as CDAI > 10; provision of informed consent; and fulfillment of the reimbursement criteria for treatment with SC abatacept under provincial or private health insurance reimbursement coverage. Patients were excluded if they had received abatacept (SC or intravenous) prior to the enrolment visit; had failed more than 1 prior bDMARD therapy; and/or had a history of autoimmune disease or any joint inflammatory disease other than RA with the exception of concomitant secondary Sjogren’s syndrome.